Healthcare providers depend on access to medications and clinical preparations to support patient care across a variety of practice settings. From specialty clinics and physician offices to hospitals and other healthcare facilities, medication sourcing involves considerations such as product availability, quality standards, regulatory requirements, and the needs of individual patients.
Within the pharmaceutical supply landscape, 503B outsourcing facilities serve a distinct role by preparing compounded medications for healthcare professionals under a specific federal regulatory framework.
Established under the Drug Quality and Security Act of 2013, Section 503B of the Federal Food, Drug, and Cosmetic Act provides a pathway for registered outsourcing facilities to compound medications that may be distributed to healthcare providers without first obtaining prescriptions for individually identified patients, provided applicable statutory conditions are met.[1,2]
Understanding the role of these facilities, their regulatory requirements, and the preparations they offer can help healthcare professionals make informed decisions about sourcing compounded medications for clinical use.
What Is a 503B Outsourcing Facility?
A 503B outsourcing facility is a facility that elects to register with the U.S. Food and Drug Administration (FDA) under Section 503B of the Federal Food, Drug, and Cosmetic Act.
Unlike traditional 503A compounding pharmacies, which generally prepare medications pursuant to valid prescriptions for identified individual patients, 503B outsourcing facilities may compound eligible medications for healthcare providers to maintain as office stock, subject to applicable federal and state requirements.[1,2]
This distinction allows healthcare professionals to obtain certain compounded preparations for administration within their practices without requiring a patient-specific prescription before the medication is distributed.
503B outsourcing facilities operate under federal requirements that include:
- Compliance with applicable current Good Manufacturing Practice (cGMP) regulations.
- FDA inspections conducted according to a risk-based schedule.
- Reporting certain adverse events to the FDA.
- Submitting required compounded drug product reports.
- Meeting applicable labeling and other statutory requirements.[1,3]
These requirements establish a regulatory framework that differs from traditional patient-specific compounding.
Importantly, compounded medications produced by 503B outsourcing facilities are not FDA-approved and do not undergo the same premarket review process as FDA-approved medications.[3]
Understanding the Difference Between 503A and 503B Compounding
Although both 503A pharmacies and 503B outsourcing facilities prepare compounded medications, they operate under different regulatory frameworks and serve distinct medication sourcing needs.
503A Compounding Pharmacies
Section 503A generally addresses traditional pharmacy compounding performed pursuant to valid prescriptions for identified individual patients.
This model supports individualized medication needs when a compounded preparation is determined to be appropriate by a licensed healthcare professional.
503B Outsourcing Facilities
Section 503B establishes a separate framework for registered outsourcing facilities that may prepare eligible compounded medications for healthcare providers without first receiving patient-specific prescriptions.
These facilities are subject to cGMP requirements and additional federal oversight, including product reporting and applicable labeling requirements.[1,2]
Both models play important roles in healthcare. Understanding their differences helps providers evaluate which sourcing pathway may be appropriate for their clinical needs.
The Role of 503B Outsourcing Facilities in Clinical Supply
503B outsourcing facilities provide an additional sourcing pathway for certain compounded medications used in professional healthcare settings.
Their role extends beyond medication preparation to include operations conducted within a regulatory framework addressing manufacturing processes, quality systems, documentation, and product reporting.
Supporting Clinical Inventory Planning
Healthcare practices must consider medication availability when planning for patient care and clinical procedures.
Under the 503B framework, eligible compounded preparations may be ordered for office stock rather than requiring a prescription for an individually identified patient before distribution.[2]
This provides healthcare professionals with an additional sourcing option when evaluating clinical inventory needs, subject to product eligibility, availability, and applicable regulations.
Supporting Provider-Directed Treatment
The use of compounded preparations extends across multiple areas of clinical care, including hormone health, specialty medicine, and other provider-directed treatment settings.
Depending on the facility’s product portfolio, 503B outsourcing facilities may prepare medications in different strengths, formulations, and dosage forms.
The selection and administration of compounded medications remain the responsibility of qualified healthcare professionals, based on clinical judgment, individual patient needs, and applicable requirements.
Operating Under Established Quality Requirements
Quality considerations are an important part of medication sourcing.
503B outsourcing facilities are subject to applicable cGMP regulations, which address manufacturing processes, facilities, equipment, personnel, documentation, and quality controls.[1]
These requirements differ from the regulatory framework governing traditional 503A compounding pharmacies.
Healthcare providers should also understand that FDA registration does not constitute FDA approval of an outsourcing facility’s compounded medications or confirmation that the facility complies with all applicable requirements.[3]
Wells Pharmacy Network’s 503B Outsourcing Facility in Dyersburg, Tennessee
Wells Pharmacy Network operates a 503B outsourcing facility in Dyersburg, Tennessee, supporting healthcare professionals through the preparation of compounded medications for clinical use.
The facility’s portfolio is centered on hormone pellet preparations and supporting clinical products, providing healthcare professionals with access to various formulations intended for provider-directed administration.
As part of Wells Pharmacy Network’s broader compounding operations, the Dyersburg facility serves a distinct role from WPN’s 503A pharmacy in Ocala, Florida, which focuses on patient-specific prescriptions.
Supporting Hormone Health Through Compounded Preparations
Hormone therapy is one area of clinical practice in which healthcare professionals may evaluate compounded preparations based on individual patient needs.
WPN’s Dyersburg 503B facility offers a portfolio of hormone pellet preparations, including:
Testosterone Pellets
Available in multiple strengths and formulations, including cholesterol- and stearic acid-based preparations. The portfolio includes testosterone pellet strengths ranging from 12.5 mg to 200 mg, with available strengths varying by formulation and pellet size.
Testosterone / Anastrozole Combination Pellets
Combination preparations containing testosterone and anastrozole in specified strengths, including 100 mg / 4 mg, 200 mg / 8 mg, and 200 mg / 20 mg.
Estradiol Pellets
Available in multiple strengths, including 10 mg, 12.5 mg, 15 mg, 20 mg, and 25 mg, for consideration by qualified healthcare professionals when clinically appropriate.
Progesterone Pellets
The facility’s portfolio also includes a 50 mg progesterone pellet preparation.
These compounded hormone preparations are intended for use by qualified healthcare professionals based on patient-specific clinical considerations. Compounded hormone therapies are not FDA-approved, and their safety and effectiveness have not been established through FDA premarket review.
Additional Clinical Preparations and Supplies
Beyond hormone pellets, the Dyersburg portfolio includes additional products associated with clinical procedures and provider-administered care.
These include:
- Benzocaine / Lidocaine / Tetracaine (BLT) Numbing Cream: A compounded topical preparation containing benzocaine 20%, lidocaine 6%, and tetracaine 4%.
- Pellet Trocar Kits: Disposable and reusable options available in different sizes and materials to support pellet implantation procedures.
Together, these offerings reflect the facility’s focus on hormone-related compounded preparations and associated clinical products.
Healthcare professionals should consult Wells Pharmacy Network for current product availability, strengths, formulations, and ordering requirements.
What Healthcare Providers Should Consider When Selecting a 503B Outsourcing Facility
When evaluating a 503B outsourcing facility, healthcare professionals should consider several factors beyond the availability of a particular compounded medication.
These considerations may include:
- Regulatory Status: Confirming the facility’s registration and reviewing publicly available FDA information.
- Quality Systems: Understanding the facility’s approach to manufacturing controls, testing, documentation, and applicable quality requirements.
- Product Information: Reviewing available formulations, strengths, dosage forms, labeling, and relevant product documentation.
- Clinical Appropriateness: Evaluating whether a compounded preparation is suitable for the intended patient and clinical application.
- Ordering and Distribution Requirements: Understanding applicable requirements for purchasing, receiving, storing, and administering compounded medications.
The FDA maintains publicly available information about registered outsourcing facilities, including inspection and regulatory information, which healthcare organizations may review as part of their sourcing decisions.[4]
Because compounded medications are not FDA-approved, healthcare professionals should carefully consider the available evidence, potential risks, and appropriateness of each preparation for its intended use.[3]
Supporting Provider-Directed Care Through Compounding
503B outsourcing facilities occupy a distinct position within the pharmaceutical supply landscape by providing a regulatory pathway for the preparation and distribution of eligible compounded medications for professional healthcare use.
Through its Dyersburg, Tennessee, 503B outsourcing facility, Wells Pharmacy Network supports healthcare professionals with a portfolio centered on compounded hormone pellets and associated clinical preparations.
Alongside WPN’s 503A patient-specific compounding operations, the Dyersburg facility represents another component of the organization’s approach to serving healthcare providers with different medication sourcing needs.
Understanding the roles of 503A and 503B facilities can help healthcare professionals evaluate compounded medication sourcing options while considering regulatory requirements, product information, and individual patient needs.
Learn More About Wells Pharmacy Network’s 503B Offerings
Healthcare professionals interested in learning more about the compounded preparations available through Wells Pharmacy Network’s Dyersburg 503B outsourcing facility can visit www.wellsrx.com or contact the WPN team for current product information and ordering requirements.
For healthcare professional education only. Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Product availability and use are subject to applicable federal and state requirements.
References
- U.S. Food and Drug Administration. Information for Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
- U.S. Food and Drug Administration. Human Drug Compounding Laws. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
- U.S. Food and Drug Administration. Questions and Answers: Outsourcing Facility Registration. https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- U.S. Food and Drug Administration. Registered Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Wells Pharmacy Network. 503B Purchase Order Form. August 27, 2026. Internal product and ordering reference.
Important Information: Compounded drugs are not FDA-approved. FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Compounded medications should only be prescribed when an FDA-approved medication does not meet the medical needs of an individual patient. The information provided here is intended for healthcare professional education and is not intended to diagnose, treat, cure, or prevent any disease.
